Overview

Open-Label Study of Safety of H1337 in Healthy Volunteers

Status:
COMPLETED
Trial end date:
2024-10-14
Target enrollment:
Participant gender:
Summary
The trial will evaluate the safety of one dose regimen of H-1337 \[1% twice daily (b.i.d.)\] in both eyes in healthy volunteers.
Phase:
PHASE1
Details
Lead Sponsor:
D. Western Therapeutics Institute, Inc.